相关实验视频
Updated: Jan 16, 2026

07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
9.3K
儿科临床医生遵守花生过敏预防指南:一项随机试验
Ruchi S Gupta1,2, Lucy A Bilaver1, Jialing Jiang1
1Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Pediatrics
|October 5, 2025
概括
一项新的干预措施显著改善了儿科医生遵守婴儿早期引入花生指南的情况,这是预防花生过敏 (PA) 的关键步骤. 如果广泛采用,这种方法可以降低PA发生率.
科学领域:
- 过敏和免疫学 过敏和免疫学
- 儿科医学 儿科医学
- 临床试验研究 临床试验研究
背景情况:
- 2017年美国指南建议为婴儿提前引入花生,以预防花生过敏 (PA).
- 儿科临床医师对这些指导方针的遵守率特别低.
- 旨在减少儿童早期花生过敏的干预 (iREACH) 试验旨在解决这种坚持差距.
研究的目的:
- 评估多方面干预措施在改善儿科临床医生遵守PA预防指南方面的有效性.
- 评估干预对低风险和高风险婴儿遵守指南的影响.
主要方法:
- 一个基于实践的,集群随机试验,涉及30个儿科实践.
- 干预组接受了教育,电子健康记录嵌入的临床决策支持 (CDS) 和视觉辅助工具.
- 对照组没有接受干预;通过健康儿童访问的EHR数据记录了坚持.
主要成果:
- 在低风险婴儿中,干预临床医生显示了83.7%的坚持,而对照组的34.7% (OR,14.6).
- 在高风险婴儿中,干预组的坚持率为26.8%,而对照组的坚持率为10.4% (OR, 3.1).
- 该干预措施显著改善了两组风险组的坚持 (P < .001 低风险,P = .03 高风险).
结论:
- 一个多方面的教育干预,包括CDS工具,有效地提高了临床医生遵守花生过敏预防指南.
- 这种干预措施的成功实施和传播有可能降低花生过敏的总体发病率.
- 这项研究强调了有针对性的干预措施的重要性,以弥合临床指南和实践之间的差距.
相关概念视频
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
242
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
242
Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Pharmacokinetics in Pediatric Patients: Drug Metabolism
192
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
192
Pharmacokinetics in Pediatric Patients: Drug Distribution
252
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
252
Allergic Reactions
32.0K
Overview
32.0K
Blinding
3.8K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
3.8K

